Omiloxetine
Omiloxetine (omiloextinum, omiloxetino INN)[1] was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.[2][3]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H25F2NO4 |
Molar mass | 465.497 g·mol−1 |
3D model (JSmol) | |
Density | 1.3±0.1 g/cm3 |
Melting point | 228.65 °C (443.57 °F) |
Boiling point | 587.2 °C (1,089.0 °F) |
Solubility in water | 0.0015 mg/mL (20 °C) |
SMILES
| |
InChI
|
Rafael Foguet also patented Abaperidone.
References
- "Proposed INN: List 76" (PDF). WHO Drug Information. 10 (4): 212–213. 1996.
- Terencio J (2005-12-05). "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. Archived from the original on 2016-03-07. Retrieved 2012-05-19.
- De Lecea C (2003-12-08). "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. Archived from the original on 2016-03-07. Retrieved 2012-05-19.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.